“…For instance, Wexler et al (Wexler et al 1996) reported 67% subclinical cardiotoxicity in control pediatric patients treated with doxorubicin, but only 22% in patients treated with doxorubicin and dexrazoxane. Pediatric studies with dexrazoxane have included patients with Ewing's sarcoma or related diseases (Wexler et al 1996), leukemia (Lipshultz et al 2002), osteosarcoma (Rubio et al 1995), and various mixed groups such as hepatoblastoma, Wilms tumor, non-Hodgkin lymphoma, and neuroblastoma (Bu'Lock et al 1993;Schiavetti et al 1997).…”